PET/MRI scan to guide treatment in HER2+ brain metastatic breast cancer
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests a special PET/MRI imaging scan using a labeled drug to help doctors evaluate HER2+ breast cancer that has spread to the brain. It focuses on patients who plan to receive fam-trastuzumab deruxtecan, a targeted cancer medicine, and aims to see how well the scan can support treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can give informed consent (or your legal representative can), and you’re age 18 or older.
- You have HER2-positive metastatic breast cancer that has spread to the brain (brain metastases).
- You can do treatment activities rated ECOG 0–2 (generally: fully active to limited but able to care for yourself).
- Your heart function is good enough for treatment (left ventricular ejection fraction over 50%) and you do not have certain recent or unstable heart problems.
- Your blood counts and organ labs are within limits: ANC > 1.5, platelets > 100, hemoglobin > 9, and kidney/liver tests meet thresholds.
- You’re scheduled to start fam-trastuzumab deruxtecan and you have at least one brain lesion over 1.5 cm on MRI (unless excluded for needing urgent local treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new type of PET scan (called FAPI) to see if it can help predict how well T-DXd (Enhertu) works on breast cancer that has spread to the brain. Participants will get T-DXd as planned and have the scan before starting treatment.
This trial tests a combination of a targeted cancer drug (T-DXd) with precise radiation to the brain for people with HER2-positive breast cancer that has spread to the brain. It aims to see if this combination can better control the brain tumors while being safe.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
This trial tests whether adding radiation therapy to a targeted cancer drug (trastuzumab rezetecan) is better than the drug alone for women with HER2-positive breast cancer that has spread to the brain. If you have untreated brain tumors from this type of breast cancer, this study aims to find the best way to stop them from growing.
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.